Validea Detailed Fundamental Analysis

Validea's guru fundamental report indicates that Bristol-Myers Squibb (BMY) receives an 88% rating based on their P/B Growth Investor model, which is based on the strategy of Partha Mohanram and focuses on low book-to-market stocks with sustained future growth characteristics; the analysis highlights strengths in book/market ratio, return on assets, and cash flow metrics, but notes a failure in research and development to assets, suggesting a mixed outlook despite the overall positive rating.

Analysis

Bristol-Myers Squibb (BMY) has received an 88% rating from Validea's P/B Growth Investor model, based on Partha Mohanram's strategy, indicating a notable alignment with criteria for low book-to-market stocks poised for sustained future growth. This score suggests the model has some interest in the stock. The company demonstrates strength across several fundamental metrics, passing tests for its book/market ratio, return on assets, cash flow from operations to assets, the relationship between cash flow and return on assets, return on assets variance, sales variance, advertising to assets, and capital expenditures to assets. However, a critical point of divergence from the model's ideal profile is BMY's failure to meet the 'RESEARCH AND DEVELOPMENT TO ASSETS' criterion. This specific underperformance in R&D investment relative to assets, despite an otherwise strong fundamental profile, presents a key consideration for a large-cap growth stock in the Biotechnology & Drugs industry, where R&D is typically a significant driver of future value.

Key Decisions for Investors

• Investors employing growth strategies that prioritize low book-to-market ratios and strong fundamental characteristics, as per Partha Mohanram's model, may find BMY's 88% rating and positive signals on metrics like ROA and cash flow to be of interest.
• A key consideration is BMY's 'FAIL' on the 'RESEARCH AND DEVELOPMENT TO ASSETS' metric; investors should conduct further investigation into the company's R&D pipeline and strategy to assess potential impacts on long-term growth, particularly within the R&D-intensive pharmaceutical sector.
• While the overall model score is positive, the specific weakness in R&D investment warrants careful evaluation against the otherwise favorable growth indicators before initiating or adjusting positions in BMY.